← REGULATORY CHANGES
FEDERAL REGISTER · RULENovember 21, 2023

Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format

Document type
Rule
Agency
Health and Human Services Department
Published
November 21, 2023
Effective
May 20, 2024
Document number
2023-25428
ABSTRACT

The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend its regulations concerning direct-to- consumer (DTC) advertisements (ads) for human prescription drugs presented in television or radio format and stating the name of the drug and its conditions of use (DTC TV/radio ads). Specifically, the final rule implements a requirement of the Federal Food, Drug, and Cosmetic Act (FD&C Act), added by the Food and Drug Administration Amendments Act of 2007 (FDAAA), that in such DTC TV/radio ads, the major statement relating to side effects and contraindications must be presented in a clear, conspicuous, and neutral manner. As directed by FDAAA, FDA is establishing standards to determine whether the major statement in DTC TV/radio ads is presented in a clear, conspicuous, and neutral manner.

Abstract as published in the Federal Register.

PROFESSIONAL CHANGE REPORT

See the structure of SPEQ’s reviewed analysis

Explorer members can open three bounded, human-reviewed previews each month. Full relationships, analysis, and implementation implications remain protected.

Sign in free to preview →
CHECKING ACCESS

Checking your Professional access…

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →
PUT THIS CHANGE TO WORK
GxP HorizonWhere regulation is heading next →Decode the standardsThe requirements this rule touches →All regulatory changesBrowse the live Federal Register feed →

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.